The relative simplicity of obtaining germline DNA combined with an established mechanism through which HSD3B1 inheritance confers resistance to castration using an extragonadal androgen-dependent mechanism strongly supports integration of HSD3B1 into prostate cancer clinical trials in development, and thus the potential role of HSD3B1 in routine clinical care remains to be determined. This evidence concerns the gene HSD3B1 and prostate carcinoma.